How Does Cooper Companies Company Work?

CooperVision designs, manufactures, and markets a wide array of soft contact lenses. Their product range addresses various vision needs, including myopia, hyperopia, astigmatism, and presbyopia. This segment serves both contact lens wearers and eye care professionals globally.

CooperSurgical focuses on women's health and fertility, offering a broad spectrum of medical devices and solutions. Their portfolio supports areas such as assisted reproductive technology, contraception, and gynecological surgery.

CooperVision's commitment to optical science research and development, alongside collaborations with eye care professionals, drives its product innovation. Manufacturing facilities are strategically located across Puerto Rico, New York, Costa Rica, Hungary, and England, ensuring a global supply chain.

CooperSurgical's value proposition centers on delivering high-quality healthcare solutions that enhance the well-being of women, babies, and families. They distribute specialized products to healthcare providers and fertility clinics worldwide, impacting patient care significantly.

Significant acquisitions have been central to CooperCompanies' growth strategy. Notable examples include the 2005 acquisition of Ocular Sciences Inc. for CooperVision, and more recent strategic moves like the December 2021 purchase of Generate Life Sciences for $1.6 billion, the March 2022 acquisition of Cook Medical's reproductive health business for $875 million, and the August 2024 deal for obp Surgical at approximately $100 million, all enhancing CooperSurgical's capabilities.

Despite facing operational hurdles, such as a system upgrade issue in CooperSurgical's U.S. distribution center during Q2 2024, the company demonstrated resilience. Even with acknowledged macroeconomic headwinds and tighter channel inventories in fiscal Q2 2025, CooperCompanies maintained its outlook to outperform the market.

CooperCompanies holds a commanding position in the U.S. contact lens market, capturing roughly one-fourth of the market share. This strong presence is supported by a robust portfolio of brands, including Proclear, Biofinity, MyDay, and Clariti, catering to a wide range of vision correction needs.

The company's commitment to research and development, particularly in areas like myopia management with MiSight 1 day lenses, offers significant growth potential. Furthermore, its extensive global footprint, with products available in over 130 countries and more than 50% of revenue generated internationally, provides a buffer against localized economic fluctuations.

CooperVision holds approximately a 25% global market share in contact lenses, ranking it among the top three. CooperSurgical is a leader in fertility and women's health, bolstered by a comprehensive product range and strategic acquisitions.

The company faces risks from foreign currency fluctuations and rising effective tax rates, which were 36.1% and 33.6% for the three and nine months ended July 31, 2024, respectively. Integration of acquisitions and regulatory pressures also present challenges.

Future growth is targeted through expansion in emerging markets and continuous product innovation, especially in myopia management and fertility solutions. The company's approach to market emphasizes taking market share and expanding profitability.

For fiscal year 2025, total revenue is projected between $4,107 million and $4,146 million. Non-GAAP diluted EPS is expected to be between $4.05 and $4.11.